Quick Facts: Therapeutic Areas

• Assists in managing gastrointestinal stromal tumor (GIST) in patients whose disease has progressed or who experienced intolerance to imatinib mesylate.
• Is indicated for the treatment of advanced renal cell carcinoma (RCC).
• Supports the management of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) that are locally advanced or metastatic and unresectable.

---

What Suanatem treats: main uses and benefits

Sunitinib (referred to here as Suanatem) is indicated for the treatment of specific types of cancer. The medication assists in managing advanced renal cell carcinoma (RCC) in adults. It is also used to address gastrointestinal stromal tumor (GIST) in patients after the disease shows progression following treatment with another specific agent, or for those who cannot tolerate that prior therapy. Additionally, sunitinib is an option for patients with progressive, well-differentiated pancreatic neuroendocrine tumors (pNET). This includes disease that is locally advanced or metastatic and cannot be removed surgically (unresectable). The drug is used to address these serious conditions under the direction of a healthcare professional.

The medicine may be used in the context of adjuvant treatment for adult patients with high risk of recurrent RCC following a kidney removal procedure (nephrectomy). The therapeutic goals focus on supporting disease management for these specific indications.

Eligibility Map: Who Can and Cannot Use Suanatem

Official regulatory documents define the population eligibility for Suanatem (Sunitinib) by specifying approved age groups, contraindications, and mandatory restrictions.

Eligibility Scope	Status as Per Official Labeling
Populations Allowed	Adults (18 years and older) for all approved uses.
Populations Contraindicated	Patients with known hypersensitivity to sunitinib or its components.
Age-Related Status	Use in pediatric patients (under 18) is not established and not recommended.
Pregnancy/Lactation Status	Contraindicated in pregnant women due to fetal harm risk; breastfeeding is not recommended.
Hepatic Function	Not recommended for patients with severe hepatic impairment (Child-Pugh Class C) as use has not been studied.
Renal Function	Use is permitted in all degrees of renal impairment or in End-Stage Renal Disease (ESRD) patients on hemodialysis.

---

Official eligibility statements primarily establish adults as the only approved age group. The use is conditionally restricted for patients with severe liver issues and permanently discontinued for patients who develop clinical Congestive Heart Failure or confirmed severe dermatologic reactions.

Suanatem Interactions with other medicines and products

This section outlines the documented interactions of this product with other medicines, classes of drugs, or specific substances as stated in official government regulatory information.

Interaction Scope	Details from Regulatory Documents
Medicinal Product Categories	Anticoagulants (warfarin), Hypoglycemic agents (sulfonylureas), Diuretics (thiazides), Potassium-sparing diuretics, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Methotrexate, Phenytoin, Digoxin, Rifampicin, Cyclosporine, Pyrimethamine.
Specific Interacting Medicines	Warfarin, Sulfonylureas (e.g., glipizide, glyburide), Phenytoin, Methotrexate, Digoxin, Pyrimethamine, Dofetilide.
Mechanistic Basis of Interactions	Inhibition of hepatic metabolism (CYP2C9 inhibition), Displacement from protein binding sites, Competition for renal tubular secretion, and Additive pharmacological effects (e.g., hyperkalemia, bone marrow suppression).
Interaction-Related Restrictions	Concomitant use with Dofetilide is generally contraindicated due to the potential for significant increases in dofetilide plasma concentrations, increasing the risk of serious ventricular arrhythmias.

The official regulatory documents highlight the potential for multiple types of clinically significant interactions with this product. One primary concern involves medicines with a narrow therapeutic index, such as the anticoagulant warfarin and the anti-epileptic phenytoin, where the product can increase their blood concentrations, necessitating close monitoring and possible dose reduction. A second major area of concern is the risk of hyperkalemia when combined with medicines that also elevate potassium, such as ACE inhibitors or potassium-sparing diuretics. Furthermore, the interaction with Dofetilide represents a specific, high-level interaction constraint, requiring that the combination be avoided entirely due to the severity of the potential cardiac risk. These statements strictly define the use of the product in combination with other therapeutic agents.

Suanatem is a fixed-combination antimicrobial agent composed of Spiramycin and Metronidazole. The pharmacodynamic action is bifunctional, targeting distinct bacterial processes.

Spiramycin, a macrolide, enters susceptible bacterial cells and acts as a reversible inhibitor of protein synthesis. It binds to the 50S subunit of the bacterial ribosome, specifically preventing the translocation step. This action arrests the peptidyl transferase activity and stops the elongation of the polypeptide chain, resulting in bacteriostasis.

Metronidazole, a nitroimidazole, is a prodrug that requires anaerobic or microaerophilic metabolism. Once inside the bacterial cell, the nitro group is chemically reduced by the low-redox potential of electron transport proteins (e.g., ferredoxins), generating highly reactive cytotoxic free radicals and short-lived intermediates. These active species damage bacterial DNA, inducing strand breaks and helical destabilization. This molecular disruption impairs DNA repair, replication, and transcription, leading to a bactericidal effect on susceptible organisms. The combined action provides broad modulation of the microbial population.

Suanatem is administered orally, with the dosage and schedule strictly defined by the regulatory-approved usage context. The medicine is presented as a capsule that must be swallowed whole with water and can be taken independent of meals.

The most common starting daily dose for certain approved indications, including advanced kidney cancer and gastrointestinal stromal tumors, is 50 mg. A different starting dose of 37.5 mg is typically used for specific neuroendocrine tumors. The prescribed dosage may be adjusted as necessary using standardized increments or decrements of 12.5 mg, which follows specific procedural protocols outlined in the official labeling.

Usage follows two distinct regulatory-defined schedules. For many approved uses, administration follows a cyclic pattern of 4 consecutive weeks of treatment followed by 2 weeks without the medicine. For specific neuroendocrine tumors, a continuous daily schedule is utilized, without planned off-treatment periods. Starting doses generally do not require modification for patients with mild to moderate hepatic impairment or those with mild to severe renal impairment.

If a daily dose is missed, it should not be replaced by taking a double dose. Instead, the patient should resume the regular schedule at the next designated time. The total duration of use for certain types of kidney cancer following surgery (adjuvant use) is limited to a maximum of nine 6-week cycles, while other uses continue based on established clinical criteria.

Suanatem: Recent Clinical Evidence

---

Evidence for use in Advanced Periodontal Disease

Research has explored the use of this combination medicine for chronic and advanced gum disease, typically as an adjunct to mechanical cleaning procedures. Studies were conducted in adult populations, and researchers examined short-term symptom patterns and outcomes related to specific markers of disease activity. Trials monitored clinical parameters such as changes in the clinical attachment level and probing depth. The long-term effects are not fully established regarding clinical and microbiological stability, as research indicates that follow-up durations were limited in many initial trials.

---

Evidence for use in Odontogenic Infections

Research describing the use of this medicine for acute, dental-related infections, such as localized cellulitis or abscesses, primarily involves randomized, comparative clinical trials. These studies focused on outcomes related to the measurement of acute infection signs and physical discomfort over a brief time interval. The evidence is limited regarding long-term outcomes following the acute treatment phase. Comparative evidence is lacking for certain patient subgroups, and results apply only to the populations studied.

---

Long-Term Follow-up and Durability of Findings

Information for long-term outcomes is not fully established for either indication. For periodontal disease, studies have observed patient patterns for up to six months. However, evidence is limited regarding the medicine's association with preventing future episodes or recurrences, and research does not provide extensive insight into the durability of change years after the medicine was initially evaluated.

---

Evidence in Specific Patient Populations

The vast majority of the research for this combination was studied in cohorts of adults. Evidence is limited regarding specific populations such as children, older adults with significant medical conditions, or patients with compromised immune systems. Data for these groups remain insufficient, and findings are often uncertain due to modest sample sizes in relevant studies.

---

What is Still Uncertain About the Research for Suanatem

The research describes certain limitations, including limited follow-up durations, which means long-term effects are not fully established. The evidence quality varies across studies, and some trials used small sample sizes, limiting the overall certainty of findings. Research highlights what is known, but provides context about group patterns, not individual predictions.

Key Studies & References Amoxicillin-Metronidazole vs Spiramycin-Metronidazole in the Treatment of Odontogenic Circumscribed Cellulitis: Randomized Clinical Trial in Odontostomatology

Common questions about Suanatem (FAQ)

---

Q: How is Suanatem different from other medicines for the same condition?

A: Suanatem is an official combination medicine that delivers two different active substances in a single tablet. It is composed of Metronidazole, a nitroimidazole antibacterial, and Spiramycin, a macrolide antibacterial. This intentional pairing is designed to provide activity by targeting two distinct pathways in susceptible microorganisms, as described in regulatory documents.

---

Q: Can Suanatem make me feel tired or drowsy?

A: Official regulatory documents indicate that drowsiness is listed as a possible adverse effect. This effect is associated with the metronidazole component of the medicine. Refer to the comprehensive safety information section for a full list of possible side effects.

---

Q: Can Suanatem affect my mood or mental clarity?

A: Regulatory product information notes that psychiatric effects are possible, though rare. These have included reports of effects such as confusion, hallucinations, and depressed mood associated with the metronidazole component. Official information is provided to make patients aware of these possibilities.

---

Q: Are there any common foods or drinks that interact with Suanatem?

A: Official instructions state that Suanatem can be taken independent of meals. However, regulatory guidelines generally advise against the use of alcohol and products containing alcohol during and for a period after treatment because of the potential for an adverse reaction. The official documentation provides a complete review of known interactions and restrictions.

---

Q: Is it normal to feel a mild headache when starting Suanatem?

A: Headache is listed in regulatory documents as a common possible side effect associated with the metronidazole component. Refer to the official patient information leaflet for a complete description of commonly reported effects.

---

Q: Can Suanatem be taken with alcohol (seeking official safety classification)?

A: Regulatory guidelines generally advise against this. The official product information does not recommend the use of alcohol during the period of treatment and for at least three days after the final dose. This is due to the potential for a specific type of adverse reaction linked to the metronidazole component.

---

Q: Does Suanatem affect blood pressure or heart rate?

A: Official documents note that certain adverse reactions, particularly when the medicine is combined with alcohol, can include symptoms such as rapid heartbeat and low blood pressure. The full regulatory safety section contains information regarding general cardiovascular effects.

---

Q: Does Suanatem interact with oral contraceptives?

A: The official product information generally describes the active ingredients, which include a macrolide (Spiramycin) and a nitroimidazole (Metronidazole), as not expected to reduce the effectiveness of most hormonal oral contraceptives.

---

Q: Are there restrictions on driving or operating machinery while taking Suanatem?

A: Official patient information advises individuals to be aware of the possible risk of effects like dizziness, confusion, hallucinations, or seizure. If these disorders occur, official guidance states that you should avoid driving or operating machinery.

---

Q: Is it possible to be allergic to Suanatem?

A: Official labeling lists a known hypersensitivity to the active substance or its components as a condition that is described as a restriction on use. Furthermore, GHS safety classifications for the product highlight the potential for an allergic skin reaction or respiratory sensitization.

---

Q: Where can I find the official patient information leaflet for Suanatem?

A: Official patient information leaflets, known as Patient Information/Consumer Medication Information (CMI) or package inserts, are factual documents from regulatory bodies. These resources are typically available through the websites of national regulatory authorities like the FDA and EMA, or through resources such as the NIH’s MedlinePlus.

---

Q: Why do some people say they felt dizzy when they first started Suanatem?

A: Dizziness is listed as a possible side effect in the official regulatory documents for the metronidazole component. As with many medicines, possible side effects can sometimes be more noticeable when a person first begins taking the medication.

---

Q: Is Suanatem considered generally 'safe' by health regulators?

A: Suanatem is an approved combination medicine, which means that regulatory agencies have determined that the product is suitable for its specific authorized uses, considering both its benefits and known risks. Official safety documentation is focused on defining its known hazards and the risk minimization measures that must be followed during use.

---

Q: What is known about the effects of Suanatem in pregnant or breastfeeding populations?

A: The official labeling states the product is contraindicated in pregnant women due to the risk of fetal harm. Regarding infants, the official labeling includes a statement that breastfeeding is not recommended because components of the medicine are known to pass into breast milk.

---

Q: Has Suanatem been studied in pediatric populations?

A: Official documents state that the use of Suanatem in pediatric patients (those under 18) is not established and is not recommended.

---

Q: Does taking Suanatem with food change how it works?

A: The official administration instructions for Suanatem state that the medicine can be taken independent of meals. This indicates that the presence or absence of food does not significantly affect the way it should be administered.

---

Q: How long does Suanatem stay in your system?

A: Official pharmacokinetic data for the metronidazole component indicates that the terminal half-life—the time it takes for half of the drug to be eliminated from the body—is approximately 5 to 7 hours in plasma.

---

Q: Is it possible for Suanatem to stop working over time?

A: The official research review notes that the long-term durability of findings is not fully established, and follow-up durations in many initial trials were limited. This means research does not provide extensive insight into the possibility of efficacy changes over very extended periods.

---

Q: Are the reported side effects of Suanatem considered temporary or long-lasting?

A: Official documents define different types of effects. Some neurological effects associated with the metronidazole component are noted as generally reversible upon discontinuation. However, the product's official safety structure also defines certain potential chronic hazards related to long-term exposure.

Storage and Handling Requirements

Official regulatory labeling dictates that Suanatem (Sunitinib) capsules must be stored at Controlled Room Temperature, specifically ranging from 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat and moisture; therefore, the medicine should not be refrigerated or frozen, and storage above 30 C is not advised.

For stability, the medicine must be kept in its original container with the lid tightly closed. The desiccant, if present, should remain in the bottle. As a mandatory safety measure, this medicine must always be stored out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Suanatem, the product must not be flushed down a toilet or poured down a drain. Patients should prioritize utilizing a medicine take-back program or an official collection site for disposal. If a take-back program is unavailable, the capsules should be mixed with an unappealing substance, sealed in a container, and placed in the household trash to prevent misuse.